Recurrent Glioblastoma Clinical Trials
2 recruiting trials for Recurrent Glioblastoma. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Recurrent Glioblastoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 2: 1.
Research is led by National Institute of Neurological Disorders and Stroke (NINDS) (1), BioNTech SE (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is LMP744 (drug, 1 trial), followed by Conventional Surgery or Biopsy, Pumitamig.
Track Recurrent Glioblastoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often...
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients...
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Recurrent Glioblastoma, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Recurrent Glioblastoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Recurrent Glioblastoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.